Shao, Z., Wang, R., Zhao, R., Yu, Y., Ouyang, Q., Ren, Y., Huang, J., Yao, Y., Zhang, J., Jiang, A., Li, H., Zhang, H., Nie, J., Cheng, Q., Yao, T., Gu, S., Hou, Y., Ren, T., Liu, B., Fang, J. (2026). Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.598